Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

ChemoCentryx (CCXI) News Today

ChemoCentryx logo
Rishi Gupta's Net Worth
ChemoCentryx, Inc. stock logo
ChemoCentryx, Inc. (NASDAQ:CCXI) Receives Consensus Rating of "Hold" from Analysts
Shares of ChemoCentryx, Inc. (NASDAQ:CCXI - Get Rating) have earned an average rating of "Hold" from the six ratings firms that are presently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating on the comp
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
ChemoCentryx, Inc. stock logo
ChemoCentryx, Inc. (NASDAQ:CCXI) Given Consensus Rating of "Hold" by Brokerages
ChemoCentryx, Inc. (NASDAQ:CCXI - Get Rating) has been assigned an average recommendation of "Hold" from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation, one has assigned a buy recom
ChemoCentryx (NASDAQ: CCXI)
Biotech Valuations Remain In a Slump - TheStreet
Amgen CEO Sees Tougher Sleddin - GuruFocus.com
ChemoCentryx, Inc. stock logo
ChemoCentryx, Inc. (NASDAQ:CCXI) Receives Consensus Rating of "Hold" from Brokerages
ChemoCentryx, Inc. (NASDAQ:CCXI - Get Rating) has earned a consensus rating of "Hold" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rati
ChemoCentryx, Inc. stock logo
ChemoCentryx, Inc. (NASDAQ:CCXI) Sees Significant Increase in Short Interest
ChemoCentryx, Inc. (NASDAQ:CCXI - Get Rating) was the recipient of a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 6,910,000 shares, an increase of 6.1% from the July 31st total of 6,510,000 shares. Based on an average trading volume of 2,240,000 shares, the days-to-cover ratio is currently 3.1 days. Approximately 11.9% of the company's shares are sold short.
Get ChemoCentryx News Delivered to You Automatically

Sign up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

Financial Prophecy (Ad)

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

CCXI Media Mentions By Week

CCXI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CCXI
News Sentiment

0.19

0.46

Average
Medical
News Sentiment

CCXI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CCXI Articles
This Week

0

0

CCXI Articles
Average Week

Get ChemoCentryx News Delivered to You Automatically

Sign up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CCXI) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners